UNSPSC 51341605: Somantadine hydrochloride

This classification denotes an antiviral agent with the molecular formula C14H25N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I505KI9F8Q, chemically known as 2-(1-adamantyl)-1,1-dimethylethylamin hydrochlorid but more generally known as somantadine hydrochloride, which bears US NIH Compound Identifier 3033453. Most nations, for tariff and trade purposes, schedule somantadine hydrochloride under HS 29213099 and SITC 51453. As of Q4 2014, SOMANTADINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Somantadine hydrochloride bears US NLM identifiers UMLS ID C2825701 and NCI Concept Code C81610. SMILES: CC(C)(C[C@]12C[C@@H]3C[C@H](C1)CC(C3)C2)N.CL.

UNSPSC 51341605 Somantadine hydrochloride, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The recent opportunities posted under this code do not involve somantadine hydrochloride or related antivirals; instead, they reflect a mismatch between the code assignment and the work actually being solicited. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking naloxone and safe drug deactivation systems—opioid-reversal and pharmaceutical waste management products unrelated to antiviral compounds. The City of Tampa's March 2026 IFB 26P00145 solicited medical and first aid supplies for the Tampa Fire Department Rescue Division, including respiratory equipment, cardiac monitoring devices, and emergency consumables. The Texas Health and Human Services Commission's April 2026 RFI HHS0017013 sought vendor capabilities for direct-to-manufacturer prescription programs and pharmacy benefit management, not specific pharmaceutical commodities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) January 2026 RFP S1070000015802 addressed generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with NDC-specific pricing requirements and an effective date of July 1, 2026—a broad pharma-procurement vehicle but not focused on somantadine or its therapeutic class.

The code shows no clear geographic concentration or pattern of repeat buyers pursuing somantadine hydrochloride procurement. Activity tagged under this code spans Florida (Seminole County), Texas (HHS Commission), Minnesota (MMCAP, administered by the state's Office of State Procurement with Oregon participation), and Florida again (City of Tampa). The mismatch between the code's name and the commodities actually being purchased—naloxone, generic pharmaceuticals, emergency medical supplies, and pharmacy benefit logistics rather than antivirals—suggests either miscoding at the source or that somantadine hydrochloride sees no active demand in recent state and local procurement. No response dates or contract awards have been identified for opportunities explicitly targeting this commodity.